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Abstract
Background: Evidence suggests a largely environmental component to non-Hodgkin’s lymphoma (NHL). Persistent
organic pollutants (POPs) including polychlorinated biphenyls (PCBs), DDE and HCB have been repeatedly implicated,
but the literature is inconsistent and a causal relationship remains to be determined.
Methods: The EnviroGenoMarkers study is nested within two prospective cohorts EPIC-Italy and the Northern Sweden
Health and Disease Study. Six PCB congeners, DDE and HCB were measured in blood plasma samples provided at
recruitment using gas-chromatography mass spectrometry. During 16 years follow-up 270 incident cases of B-cell
NHL (including 76 cases of multiple myeloma) were diagnosed. Cases were matched to 270 healthy controls by centre,
age, gender and date of blood collection. Cases were categorised into ordered quartiles of exposure for each
POP based on the distribution of exposure in the control population. Logistic regression was applied to assess the
association with risk, multivariate and stratified analyses were performed to identify confounders or effect modifiers.
Results: The exposures displayed a strong degree of correlation, particularly amongst those PCBs with similar degrees
of chlorination. There was no significant difference (p < 0.05) in median exposure levels between cases and controls for
any of the investigated exposures. However under a multivariate model PCB138, PCB153, HCB and DDE displayed
significant inverse trends (Wald test p-value <0.05). Under stratified analyses these were determined to be driven by
males and by the Diffuse Large B-Cell Lymphoma subtype. When considering those in the highest levels of exposure
(>90th percentile) the association was null for all POPs
Conclusion: We report no evidence that a higher body burden of PCBs, DDE or HCB increased the risk of subsequent
NHL diagnosis. Significantly inverse associations were noted for males with a number of the investigated POPs.
We hypothesize these unexpected relationships may relate to the subtype composition of our population, effect
modification by BMI or other unmeasured confounding. This study provides no additional support for the previously
observed role of PCBs, DDE and HCB as risk factors for NHL.
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Background
The non-Hodgkin's lymphomas (NHL) are a heteroge-
neous collection of lymphoproliferative B or T-cell ma-
lignancies that typically present as a solid tumour of
lymphoid cells in the glands [1]. Currently more than 50
different subtypes of B and T-cell NHL have been de-
fined, differing in both clinic-pathological and biological
characteristics [2]. Yet despite their widespread preva-
lence and high mortality rate, relatively little is known
about the aetiology of NHL [3].
Immune dysfunction is the underlying basis of lym-
phomagenesis and the most well established risk factor
to date is immunosuppression [4–6]. However immuno-
suppressed patients in fact account for only a small frac-
tion of cases, and the epidemiological evidence suggests
a largely environmental component to the aetiology of
NHL [7]. The reported increase in incidence of NHL,
and particularly of the more highly aggressive subtypes,
in the UK and most other Western countries since
the 1980s had been noted to mirror the worldwide
usage trends of a number of suspected chemical risk
factors, including polychlorinated biphenyls (PCBs). A
plateauing of this increase was observed to occur fol-
lowing the banning of many of these substances in
much of the world [8]. Similarly, an excess of cases
has been reported in those who are occupationally or
residentially exposed to the suggested environmental
risk factors [9]. However, the literature is inconsistent
and to date, few definitive environmental risk factors
for NHL have been agreed upon
The EnviroGenoMarkers project [10] is a nested case-
control study within two cohorts with prospectively col-
lected blood samples. The study aimed at the development
and application of a new generation of biomarkers to aid
the study of the role of environmental agents in disease. It
utilises the large-scale application of multiple –omics tech-
nologies to validate novel predictive disease biomarkers
and to explore the association of these biomarkers with
environmental pollutants using the “meet-in-the-middle”
approach [11]. “meet-in-the-middle” employs parallel ana-
lysis of exposure-biomarker relationships and metabolite-
biomarker relationships, in an attempt to understand the
causal pathway. The first step of this approach is to deter-
mine the exposure–disease relationship. The aim of this
present study was to determine the association between
NHL and prediagnositic blood plasma concentrations of
ten environmental pollutants including six PCB congeners,
DDT, DDE, HCB and BDE-47.
Methods
Study subjects
The EnviroGenoMarkers study is based on 540 partici-
pants from two existing prospective cohort studies:
EPIC-Italy (n = 168) [12] and the Northern Sweden
Health and Disease Study (NSHDS, n = 372) [13] which
have been described in detail previously. This study was
approved by the committee on research ethics at the
relevant institutions in accordance with the Declaration
of Helsinki of the World Medical Association. All partic-
ipants signed an informed consent form agreeing to pro-
vide detailed information on their dietary and life-style
habits at recruitment and to provide blood samples for
use in future research.
Both cohorts recruited healthy volunteers who under-
went standardised protocols including detailed question-
naires, anthropometric measurements, medical record
review and collection of blood samples. Recruitment for
EPIC-Italy took place between 1993 and 1998, and for
the NSHDS between 1990 and 2006. In EPIC-Italy stan-
dardized procedures were used to identify newly diag-
nosed cases of cancer based on automated linkages to
cancer and mortality registries, municipal population of-
fices and hospital discharge systems, with the exception
of Naples where follow up information was collected
through periodic personal contact. In the NSHDS in-
vasive cancers were identified by linkage with the
Swedish Cancer Registry and the local Northern
Sweden Cancer Registry.
For each lymphoma case that occurred within up to
16 years follow up a suitable cancer-free control was se-
lected by incidence matching on sex, age (+/− 2.5 years),
centre and date of blood extraction (+/− 6 months) from
the remaining cancer-free populations. More than 95%
of participants also had the same fasting status as their
matched pair at blood extraction. Information from the
two studies was integrated into a single database and
calibrated. Lymphoma cases were classified into subtypes
according to the SEER ICD-0-3 morphology codes [14].
Exposure assessment
Exposure to persistent organic pollutants (POPs) was
assessed using blood plasma. Blood samples were col-
lected in citrate (EPIC-Italy) or heparin (NSHDS) tubes
and processed by centrifugation on the day of collection
(EPIC-Italy) or within one hour of collection (NSHDS).
Aliquots (0.5 ml) were stored in liquid nitrogen tanks at
−196 °C in Italy and −80 °C in NSHDS.
All samples were measured at the National Institute
for Health and Welfare Chemicals and Health Unit,
Neulanen Research Centre, Finland The quantification
of POPs was performed by an Agilent 6890 gas chro-
matograph (GC) connected to a Waters Autospec Ul-
tima high resolution mass spectrometer (HRMS). The
GC column used was DB-5MS (J&W Scientific, 30 m,
ID 0.25 mm, 0.25 μm), and the splitless mode was used
for injection. For 43 EPIC-Italy matched pairs a slightly
different procedure was used involving an Agilent 7000B
gas chromatography triple quadruple mass spectrometry
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(GC-MS/MS) system, with a DB-5MS UI (J&W Scien-
tific, 20 m, ID 0.18 mm, 0.18 μm) GC column and the
solvent vent mode. For quality control purposes in each
batch of samples (43 batches with HRMS, 20 batches
with MS/MS) two reagent blanks were additionally pre-
pared and the average result of the blank samples sub-
tracted from the results of the real samples. Furthermore
two control samples of Standard Reference Material 1589a
(PCBs, Pesticides, BDEs, Dioxins/Furans in Humans) from
the National Institute of Standards and Technology, were
also included in each batch. Unadjusted volume-based con-
centrations of POPs, which have been found to correlate
well with lipid based concentrations, are presented [15].
Statistical analysis
All analyses were conducted on the total population as
well as stratified by cohort (EPIC-Italy and NSHDS) and
by sex where appropriate. The differences in baseline
characteristics between cases and controls were deter-
mined using Student’s t-test and chi-squared test for con-
tinuous outcomes and categorical outcomes respectively.
Exposure concentrations were explored using non-
parametric methods due to their typically non-Gaussian
distributions. Differences in concentrations between the
cohorts and by sex specific analyses were assessed using
the ranksum test while the differences between cases
and controls were assessed using the Wilcoxon signed
rank test to take matching into account. Correlation
between exposure levels was assessed using Pearson’s
correlation coefficient.
Cases were categorised into ordered quartiles based on
the distribution of exposure in the control population. A
further binary variable was created to assess whether blood
concentration exceeding ‘highly exposed’ levels, defined as
being above the 90th percentile of the control exposure
distribution, was associated with greater risk by comparing
it to those in the lowest quartile. For the remaining ana-
lyses, stratified by subtype, age group, BMI category and
time to diagnosis, exposure levels were log transformed to
normalise the distributions.
In the basic model, conditional logistic regression ana-
lyses were used to calculate odds ratios and 95% confi-
dence intervals accounting for the matching factors.
Tests for trend were performed using the Wald test stat-
istic based on the continuous quartiles. Where all con-
trols were included to maximise power, unconditional
logistic regression adjusting for the matching variables
was used. Confounding was assessed by additionally run-
ning an adjusted model; potential confounders were
identified as BMI (kg/m2), height (cm), educational level
(as a proxy for socioeconomic status), vegetable intake
(g/day), dairy intake (g/day), protein intake (g/day), total
fat intake (g/day) and alcohol consumption (g/day), based
on both a significant (p < 0.05) association with cumulative
POP concentration in the total population and a reported
association with NHL in the literature [16, 17] to ensure
biological plausibility for the included confounders.
All analyses were performed using Stata 11.3, the level
of statistical significance was set at 0.05 and all tests
were two tailed.
Results
A total of 281 incident cases were diagnosed during
follow-up; 84 from EPIC Italy and 197 from NSHDS.
Only cases of B-cell NHL were included in the final ana-
lyses, resulting in the exclusion of six cases of Hodgkin’s
Lymphoma, one case of T-cell NHL, four cases with
unknown subtype and their matched controls (n = 11
case-control pairs). There were no significant differences
between cases and controls for any of the baseline vari-
ables investigated (Table 1). The median time from
blood collection to diagnosis was 6.6 years in NSHDS
and 5.0 years in Epic-Italy, There was no association be-
tween time to NHL diagnosis and body burden of any of
the pollutants amongst the cases (p-value > 0.05).
The mean, median and range of exposure concentra-
tions in cases and controls for each investigated pollu-
tant are shown in Table 2. There was no significant
difference (p < 0.05) in median exposure levels between
cases and controls according to the Wilcoxon signed
rank test for any of the investigated exposures (Table 2).
The investigated exposures displayed a strong degree of
correlation (Additional file 1: Table S1), particularly
amongst those PCBs with similar degrees of chlorination.
For BDE-47 and DDT more than 80% of the population
had levels that could not be quantified and therefore these
exposures were excluded from further analyses. There was
no significant difference in the proportion of cases and
controls above and below the LOQ for either BDE-47 (p
= 0.706) or DDT (p = 0.425). One participant, a male con-
trol from the NSHDS was excluded from the PCB ana-
lyses as an outlier as his exposure levels were far above
the 99th percentile of the distribution for all congeners.
Table 3 shows the association between increasing
quartiles of exposure and risk of NHL, both under the
basic conditional model, and when adjusting for poten-
tial confounders. Although under the basic model a
number of significant inverse associations were observed
there was no evidence of a dose-response trend. When
adjusting on confounders, PCB138, PCB153, HCB and
DDE displayed inverse trends.
Stratified analyses by gender (Table 4) indicated that
these inverse associations were heavily influenced by males
who displayed multiple dose-dependent inverse trends with
the investigated POPs. This was not observed in females.
In analyses stratified by cohort (Additional file 1: Table S2)
inverse associations with these POPs were restricted to the
Swedish cohort.
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Information on histological subtype was available for
225 of 270 cases (83%) and the remaining 45 cases were
classified as ‘B-cell NHL, not otherwise specified’. The
most common subtype was Multiple Myeloma (MM),
which accounted for 28% of cases. The associations be-
tween log transformed exposure levels and risk for the
four largest subgroups are shown in Table 5. The signifi-
cant inverse associations were limited to Diffuse Large
B-cell Lymphoma (DLBCL). However, when a meta-
analyses of each exposure by subtype was conducted, the
I2 was 0% for all exposures except PCB170 (19.1%) and
PCB180 (30.1%), and the p values were >0.1, indicating
no significant heterogeneity between the subtypes.
Additional stratified analyses were performed to iden-
tify confounders or effect modifiers that may explain the
unexpected inverse associations. Neither age at recruit-
ment (and therefore at blood draw; Additional file 1:
Table S3) nor time to diagnosis (Additional file 1: Table
S4) appeared to be modifying the findings. Results from
the meta-analysis indicated that the percentage of
heterogeneity not due to chance (I2) was 0% for all expo-
sures, and all p-values were non-significant. When sub-
jects were stratified by BMI (Additional file 1: Table S5)
there was some indication that risk estimates tended to
decrease with BMI category, with the smallest ORs gen-
erally noted in obese participants. Effect modification by
BMI may also in part explain the observed sex discrep-
ancy, 69.6% of males were overweight or obese com-
pared with only 50.2% of females (p < 0.0001). However,
there was no significant heterogeneity between BMI
classes for any of the exposures (P > 0.05) and no con-
clusions can be drawn based on these analyses alone.
The ORs were greater than one for PCBs 118, 153, 170
and 180 in individuals whose exposure levels were above
the 90th percentile. This could be interpreted to suggest
that very high levels may increase risk, however these as-
sociations were not significant, (Table 6).
Groups of PCBs based on the properties of the conge-
ners [18] were also analysed together; dioxin-like conge-
ners (PCB#s 118, 156), non-dioxin like congeners
(PCB#s138, 153, 170, 180) and immunotoxic congeners
(PCB#s118, 138, 156, 170), and the sum total of all
PCBs. However, these were driven by the constituent
PCBs and significant inverse relationships were noted
for the non-dioxin like and immunotoxic groups (results
not shown). Categorising subjects into quartiles based
on the distribution of exposure levels in the total popu-
lation and exposure levels in cases only, did not change
the findings (results not shown).
Discussion
Exposure to PCBs and other persistent organic pollutants
has been hypothesised to be partly responsible for the in-
crease in NHL observed in the last 30 years [8, 19], which
is larger than can be explained on the basis of changes to
the classification procedures [19] or on known risk factors
alone [20]. However the literature is inconclusive [21, 22].
In this study a prospective design was used to explore the
risk of NHL associated with internal dose of six PCB
congeners, HCB and DDE, under the hypothesis that an
elevated body burden may increase future risk of this
malignancy. We report geographical and sex-specific dif-
ferences in results. In this population there was evidence
of a possible increase in risk with exposure to certain PCB
congeners in females, and a number of unexpected inverse
associations in males. Our results additionally suggest pos-
sible differences in risk by subtype but these were based
Table 1 Baseline characteristics of cases and controls
Baseline variable Case
(n = 270)
[n(%)]
Control
(n = 270)
[n(%)]
Difference
(p-value)
Cohort EPIC-Italy 84 (31.1) 84 (31.1)
NSHDS 186 (68.9) 186 (68.9)
Sex Male 133 (49.3) 133 (49.3)
Female 137 (50.7) 137 (50.7)
Mean Age (yrs) 53.08 53.09 0.989
Mean Height (cm) 169.55 168.24 0.120
Mean Weight (kg) 76.48 75.09 0.267
BMI Underweight 1 (0.4) 0 (0.0)
Normal 104 (38.5) 109 (40.4)
Overweight 121 (44.8) 118 (43.7)
Obese 40 (14.8) 39 (14.4)
unknown 4 (1.5) 4 (1.5) 0.883
Smoking status Never 121 (44.8) 134 (49.6)
Former 90 (33.3) 72 (26.7)
Current 57 (21.1) 54 (20)
unknown 2 (0.7) 10 (3.7) 0.269
Highest educational
level
None 4 (1.5) 1 (0.4)
Primary 94 (34.8) 98 (36.3)
Technical/
professional
68 (25.2) 54 (20.0)
Secondary 52 (19.3) 64 (23.7)
University/
college
47 (17.4) 42 (15.6)
unknown 5 (1.9) 11 (4.1) 0.202
Cambridge physical
activity index
Inactive 80 (29.6) 75 (27.8)
Moderately
inactive
106 (39.3) 95 (35.2)
Moderately
active
69 (25.6) 76 (28.2)
Active 14 (5.2) 23 (8.5)
unknown 1 (0.4) 1 (0.4) 0.510
Chi2 tests excluded the unknown category
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on small numbers. Stratified analyses revealed no evidence
of confounding or effect modification by age at diagnosis
or by time between blood draw and disease diagnosis.
Those in the very highest levels of exposure showed a
non-significantly increased risk for a number of PCBs.
PCBs, a mixture of synthetic chlorinated hydrocarbons
that are the products and incidental by-products of mul-
tiple industrial and agricultural processes, have recently
been upgraded to Class 1 carcinogens by the Inter-
national Agency for Research on Cancer [23]. Although
once widely used, concern about their health effects and
toxicity has led to PCBs being banned in most countries
[24]. However, these compounds are exceptionally stable,
chemically inert and highly soluble in lipids [25]. Conse-
quently they have extensively polluted the environment
and are still found in all environmental media, including
air, water, and soil which has led to bioaccumulation in
the food chain, and most people have a measurable
amount of PCBs in their bodies [21].
The evidence for an association with NHL is based on
the observed tumorogenic and carcinogenic properties
of PCBs, and in particular the dioxin-like properties ex-
hibited by the coplanar congeners [26, 27]. The dioxin-
like congeners share a biological mechanism, based on
binding to the Ah-receptor [28], with 2,3,7,8-TCDD a
compound which has previously been associated with an
increased risk of lymphoid malignancies [29]. The asso-
ciation with NHL is further supported by the known
immunosupressive and inflammatory properties of PCBs
[30], and the temporal relationship between the inci-
dence of NHL and the worldwide production of PCBs.
Although PCBs have been widely explored in relation
to NHL, the evidence has been contradictory. While
many studies report a positive association with the sum
of PCB body burden, PCB mixtures (including dioxin-
like, non-dioxin like and immunotoxic) and individual
congeners [26, 31–36], an equally large number have
found no association [37–43]. Many of the positive find-
ings come from case-control studies which are subject
to the problems of reverse causation and other bias, or
from investigations of high levels of accidental exposure
[36, 44]. Even among highly exposed occupational co-
horts the results have not been consistent [22]. Others
have utilised proxies, such as house dust, which may not
accurately reflect actual exposure [35]. Of the studies
most directly comparable with this study, those utilising
prediagnostic exposure measurements in the general
population, two [34, 45] reported an increased risk with
total PCB exposure in both sexes, while a third [32] re-
ported an increase in males. Two further studies [37, 38]
reported no significant associations for any of the inves-
tigated congeners. Even systematic reviews have been
unable to confirm or refute an association, and a causal
relationship remains to be defined [21, 22, 25, 35, 45].
The literature is similarly inconsistent for DDE and for
HCB, which showed some of the strongest inverse asso-
ciations in this population. Three case control-studies
have reported a positive association between NHL and
DDE. One was based on adipose tissue concentrations
[42] and two measured levels in blood [31, 33]. However,
in a study of serum organochlorine levels in participants
living near a municipal solid waste incinerator the relation-
ship was borderline significant and the OR indicated only a
marginal increase in risk [31]. Additionally a number of
both case-control [26, 41] and cohort [32, 37, 38] stud-
ies have reported no association. Similarly, for those
studies considering HCB; although one [33] observed a
positive association with risk, two other studies report
null findings [31, 37].
In this study of a general, non-occupationally exposed
cohort, exposure was assessed using blood concentra-
tions of eight POPs in samples taken from cancer-free
Table 2 Mean, median and range of exposure concentrations of six PCB congeners, HCB, DDT, DDE and BDE-47
Exposure LOQ Cases (n = 270) % Controls (n = 270)a Difference
p-valueb% < LOQ Median Mean Range % < LOQ Median Mean Range
PCB118 5 pg/ml 0.0% 134.7 182 (8.5, 901.6) 0.0% 147.7 175.7 (11.6, 832.1) 0.991
PCB138 5 pg/ml 0.0% 530.0 605.6 (11.0, 1810.1) 0.0% 562.3 636.4 (51.2, 2675.4) 0.276
PCB153 4 pg/ml 0.0% 1007.8 1150.9 (32.5, 3308.0) 0.0% 1086 1205.5 (120.6, 4334.1) 0.239
PCB156 2 pg/ml 0.0% 90.6 102 (19.8, 307.8) 0.0% 95.6 106.7 (15.5, 394.9) 0.186
PCB170 4 pg/ml 0.0% 326.4 375.2 (62.7, 1082.3) 0.0% 357.6 389.4 (50.4, 1291.2) 0.284
PCB180 3 pg/ml 0.0% 696.6 788.8 (139.7, 2708.8) 0.0% 727.8 807.9 (100.1, 2431.5) 0.284
HCB 25 pg/ml 0.0% 257.8 398.1 (62.5, 3604.0) 0.0% 289.2 432.5 (64.5, 3882.2) 0.198
DDT 200 pg/ml 85.9% 261.8 331.7 (206.6, 825.8) 86.7% 298.2 399.8 (218.8, 1636.9) 0.865
DDE 5 pg/ml 0.0% 2478.7 4038.4 (16.4, 30992.8) 0.0% 2675.3 4200.1 (76.4, 23858.3) 0.374
BDE-47 15 pg/ml 84.1% 23.5 34.2 (15.1, 133.4) 81.1% 25.8 95.1 (15.3, 2063.3) 0.657
LOQ limit of quantification
aPCB analyses were based on 269 controls as one participant with exposure levels above the 99th percentile was excluded
bDifferences between median concentrations in cases and controls according to the Wilcoxon signed-rank test for paired samples
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individuals at recruitment to the cohort. This provides a
point estimate of historical exposure free from recall
bias, which can be common when individuals are sur-
veyed on their long term exposure to environmental pol-
lutants. Additionally, the measure is free from disease
bias; pathological changes may affect the levels of certain
pollutants and therefore distort the association, but in
this study all participants were free of lymphoma at as-
certainment. Global restrictions in the use of POPs has
led to a reported decrease in human body burden over
the last decade: for PCBs current exposure levels are es-
timated to be half those of 20–30 years ago [46], making
it difficult to compare between populations and across
periods. However, the observed exposure levels for the
POPs were within the range of those reported in studies
of similar populations [47]. All POPs, with the exception
of PCB170, were at higher levels in the Italian cohort.
In general, inverse associations were noted for males,
while females tended to show positive, although non-
significant associations. Gender-specific differences were
Table 3 Association between NHL and quartiles of measured body burden of six PCB congeners, specified PCB functional groups,
HCB and DDE
Exposure Quartile n. Ca n. Co OR 95% CI P-value p for trend OR(adj) 95% CI P-value p for trend
PCB118 Q1 (8.46, 94.05) 80 68 1 1
Q2 (94.25, 148.04) 68 67 0.76 (0.44,1.32) 0.332 0.57 (0.31,1.08) 0.084
Q3 (148.37, 219.85) 42 66 0.45 (0.24,0.84) 0.012* 0.35 (0.17,0.72) 0.004*
Q4 (219.91, 901.63) 80 67 0.96 (0.49,1.87) 0.909 0.571 0.67 (0.3,1.49) 0.332 0.168
PCB138 Q1 (10.97, 396.03) 86 67 1 1
Q2 (399.73, 562.09) 60 67 0.67 (0.41,1.08) 0.102 0.53 (0.31,0.91) 0.021*
Q3 (562.64, 778.15) 63 67 0.63 (0.37,1.1) 0.104 0.50 (0.27,0.94) 0.031*
Q4 (778.44, 2675.35) 61 67 0.60 (0.33,1.08) 0.089 0.093 0.38 (0.18,0.78) 0.009* 0.010*
PCB153 Q1 (32.47, 812.10) 88 68 1 1
Q2 (813.60, 1083.97) 59 66 0.60 (0.36,1.03) 0.064 0.56 (0.31,1.02) 0.058
Q3 (1088.49, 1489.97) 60 67 0.54 (0.3,0.98) 0.044* 0.47 (0.24,0.93) 0.031*
Q4 (1493.70, 4334.12) 63 67 0.55 (0.3,1.04) 0.066 0.078 0.37 (0.17,0.78) 0.009* 0.011*
PCB156 Q1 (15.50, 69.69.62) 75 67 1 1
Q2 (69.95, 95.44) 71 67 0.88 (0.49,1.56) 0.654 0.9 (0.48,1.71) 0.754
Q3 (95.76, 126.68) 51 67 0.59 (0.31,1.11) 0.100 0.56 (0.27,1.16) 0.118
Q4 (126.87, 394.89) 73 67 0.86 (0.45,1.64) 0.644 0.545 0.69 (0.33,1.45) 0.326 0.228
PCB170 Q1 (50.39, 257.50) 73 67 1 1
Q2 (257.62, 358.81) 82 68 0.99 (0.59,1.66) 0.967 0.9 (0.51,1.6) 0.718
Q3 (359.10, 468.52) 43 66 0.48 (0.25,0.92) 0.028* 0.37 (0.17,0.79) 0.010*
Q4 (468.55, 1291.23) 72 67 0.83 (0.45,1.53) 0.55 0.356 0.59 (0.28,1.23) 0.160 0.091
PCB180 Q1 (100.08, 533.51) 72 67 1 1
Q2 (533.84, 730.03) 78 68 1.03 (0.61,1.73) 0.926 1 (0.55,1.81) 0.999
Q3 (730.81, 966.02) 46 66 0.57 (0.31,1.05) 0.071 0.45 (0.21,0.95) 0.035*
Q4 (966.55, 2708,83) 74 67 0.94 (0.52,1.69) 0.827 0.595 0.68 (0.32,1.42) 0.300 0.168
HCB Q1 (62.47, 181.87) 85 67 1 1
Q2 (184.78, 288.81) 62 67 0.58 (0.32,1.03) 0.064 0.52 (0.27,1.02) 0.057
Q3 (289.49, 474.86) 59 67 0.47 (0.24,0.94) 0.032* 0.28 (0.12,0.65) 0.003*
Q4 (477.00, 3882.19) 64 66 0.49 (0.22,1.07) 0.074 0.061 0.35 (0.14,0.87) 0.023* 0.014*
DDE Q1 (16.40, 1308.26) 81 67 1 1
Q2 (1310.23, 2666.60) 62 67 0.65 (0.37,1.14) 0.137 0.55 (0.28,1.05) 0.07
Q3 (2675.27, 5523.58) 68 68 0.67 (0.37,1.21) 0.186 0.40 (0.20,0.84) 0.015*
Q4 (5528.29, 30992.76) 59 66 0.55 (0.28,1.08) 0.082 0.106 0.34 (0.15,0.77) 0.010* 0.008*
OR – conditional logistic regression accounting for matching factors
OR(adj) – conditional logistic regression additionally adjusting for BMI, height, educational level, vegetables, dairy, protein, total fat, alcohol
*Significant at the 95% confidence level
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also noted in the studies by Bertrand and Laden [32, 38],
however conversely to our findings they report a positive
association in males but find no evidence of a relation-
ship in females. Other studies of PCBs have observed no
gender differences [34], however analysis of similar or-
ganochlorines suggest that sex-specific differences in the
uptake, metabolism and elimination of compounds may
result in variation in risk effects [37, 48–52] Breast feed-
ing and parity are also likely to play a role [46].
The heterogeneous nature of NHL and the differing
composition of subtypes explored in other studies may,
in part, explain the differing findings between this study
and previous work [42]. A number of the studies did not
stratify their results by subtype [8, 9, 31, 34, 37, 40, 42, 45].
Among those that did the strongest associations tended to
be noted for DLBCL [26, 32, 33], with weaker and in some
cases (non-significantly) inverse associations reported for
FL [26] and SLL/CLL [32, 38] in some studies. Even where
specific subtypes have been studied the results have been
inconsistent between studies. For example, in contrast to
much of the literature FL has been reported to be strongly
associated with PCBs in at least one study [33], while
within a single study differing directions of effect were ob-
served for DLBCL among different geographical popula-
tions [41]. Findings are further complicated by reports that
subtype-specific associations may also differ by genotype
[28] and by t(14:18) translocation status [42]. It should be
noted that none of the existing studies reported MM as a
separate subgroup, as due to its pathophysiological differ-
ences MM is often considered a distinct entity from other
B-cell NHLs. However under the most commonly used
classifications scheme today MM is classed as a B-cell
NHL (hierarchical group 4) and therefore in this study was
considered with the other B-cell subtypes. In the present
study the inverse associations appeared to be driven by
cases of DLBCL, however we report no significant evidence
of subtype heterogeneity. The differing composition of the
PCB congeners included in different studies may also ac-
count for some of the observed discrepancy between stud-
ies, particularly where a risk effect for the sum of PCBs has
been reported. It is also noted that exposure to PCBs and
how they are metabolised may differ in an occupational
setting as opposed to in the general population [8].
In order to try and further disentangle our findings, a
number of additional analyses were performed. To en-
sure that pre-diagnostic subclinical changes in cases who
were diagnosed shortly after blood draw were not modi-
fying the body burden of exogenous exposures [53],
stratification by the time to diagnosis was performed.
However there was no evidence of an effect, and simi-
larly age at diagnosis did not appear to be modifying the
results. There was, however, some weak evidence of an
effect of BMI, which may be worthy of further investiga-
tion. Risk estimates tended to decrease with BMI category,
with the smallest ORs generally noted in obese partici-
pants. This may be of interest as organochlorines are
stored in adipose tissue and therefore PCB levels in the
blood have previously been reported to be inversely asso-
ciated with weight gain, and overweight and obese individ-
uals have been observed to have lower circulating levels
[54]; this may mask an association if POPs are most meta-
bolically active on a tissue level. If BMI does act as a con-
founder this could explain the high number of inverse
associations noted in this population which contained a
high proportion (60%) of overweight and obese individ-
uals. It would also explain why inverse associations were
overrepresented in males, who had a significantly higher
proportion of overweight and obese participants. Add-
itional analyses would be required to determine whether
BMI was driving the observed gender effects or vice versa.
However, as noted in the results there was no significant
heterogeneity between BMI classes.
In this study, lipids were not adjusted for as it has
been observed that direct standardisation can introduce
bias [55], and unadjusted volume-based concentrations
of POPs have been found to correlate well with lipid
based concentrations [15]. Furthermore, the possibility
of ‘reverse causation’ and disease progression bias [53],
which are the main reasons to adjust for lipids, (in order
to take physiological pre-cancerous changes to normal
metabolic process and lipid mobilisation into account),
have been considered in these analyses. However, the
findings for BMI suggest that lipid profiles of individuals
may be important, and we cannot rule out that the lack
of lipid-adjustment may be influencing our results.
The main strength of this study is its prospective
design which protects against selection bias and it was
determined that the case and control populations were
similar with respect to baseline factors and additional
confounders. This design also allows for the determin-
ation of a temporal and causal relationship between
exposure and NHL, lacking in the majority of studies
which tend to measure post-diagnostic or post-treatment
levels. NHL or its treatment may affect metabolism and
blood concentrations of POPs [32, 54], and chemotherapy
has been observed to decrease PCB levels in the body by
up to 30% [21]. The measures of exposure assessment
were free from recall and disease bias, and were con-
ducted using validated methodologies. The use of blood
measurements has been shown to provide a reliable esti-
mate of POP body burden due to their long half-lives [38].
There were several limitations to this study. The high
correlation between exposures, particularly the PCBs, re-
stricted the ability to determine individual effects [56].
When multiple POPs were investigated in combination
no additional associations were revealed. It is possible
that there were further unmeasured confounders affect-
ing the results, for example other organochlorines or
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dioxins [45] which may bioaccumulate in parallel with
the exposures of interest. Furthermore variables relating
to the immune system, such as EBV antigens which have
been shown to interact with organochlorines in NHL
risk [39] can also not be accounted for. The estimate
of body burden is based on a single one spot expos-
ure measurement that is not necessarily representative
of lifetime exposure. Finally, the generalizability of
these findings to other populations should be consid-
ered, given the relative overrepresentation of females,
the excess of MM cases and the relatively high pro-
portion of overweight participants. In particular, these
findings should not be extrapolated into an occupa-
tional setting.
Table 6 Association between exposure and risk in ‘highly exposed’ individuals high exposure is defined as exposure levels above
the 90th of the control exposure distribution, the odds of disease are compared with those in the lowest quartile of exposure
Exposure 90th percentile control
exposure distribution
n cases (%) above
90th percentile
n controls(%) above
90th percentile
OR 95% CI p-value OR(adj) 95% CI p-value
PCB118 316.2 35(13.0) 28(10.4) 1.37 (0.76,2.45) 0.294 1.25 (0.65,2.41) 0.500
PCB138 1112.4 25(9.3) 29(10.7) 0.83 (0.45,1.52) 0.550 0.81 (0.40,1.64) 0.562
PCB153 1965.7 29(10.7) 29(10.7) 1.01 (0.56,1.81) 0.987 1.15 (0.58,2.26) 0.693
PCB156 176.4 23(8.5) 28(10.4) 0.79 (0.43,1.45) 0.447 0.89 (0.43,1.81) 0.739
PCB170 626.6 29(10.7) 29(10.7) 1.00 (0.57,1.78) 0.989 1.07 (0.55,2.06) 0.843
PCB180 1323.3 29(10.7) 28(10.4) 1.05 (0.58,1.88) 0.872 1.11 (0.57,2.14) 0.763
HCB 872.8 25(9.3) 29(10.7) 0.80 (0.41,1.55) 0.506 0.84 (0.42,1.68) 0.624
DDE 9787.7 27(10) 28(10.4) 0.95 (0.50,1.80) 0.878 1.01 (0.52,1.97) 0.978
OR – conditional logistic regression accounting for matching factors
OR(adj) – conditional logistic regression additionally adjusting for BMI, height, educational level, vegetables, dairy, protein, total fat, alcohol
Matched case-control pairs with incomplete information on potential confounders were excluded from the adjusted analyses
Table 5 Association between log-transformed body burden of six PCB congeners, specified PCB functional groups, HCB and DDE,
levels and NHL risk stratified by Subtype
Exposure CLL (n = 42) DLBCL (n = 45)
OR 95% CI p-value OR(adj) 95% CI p-value OR 95% CI p-value OR(adj) 95% CI p-value
PCB118 0.70 (0.31,1.58) 0.398 5.14 (0.56,47.08) 0.147 0.74 (0.27,2.04) 0.561 0.39 (0.06,2.68) 0.335
PCB138 0.63 (0.26,1.54) 0.309 1.33 (0.15,11.91) 0.801 0.37 (0.10,1.32) 0.126 0.33 (0.04,2.47) 0.281
PCB153 0.50 (0.16,1.52) 0.221 0.70 (0.06,7.77) 0.772 0.32 (0.08,1.26) 0.103 0.16 (0.01,1.84) 0.140
PCB156 0.57 (0.16,2.10) 0.402 1.47 (0.11,19.75) 0.773 0.25 (0.06,0.96) 0.044* 0.01 (0,0.53) 0.023*
PCB170 0.52 (0.16,1.66) 0.267 0.34 (0.03,3.61) 0.372 0.24 (0.06,1.02) 0.053 0.01 (0,0.47) 0.021*
PCB180 0.49 (0.14,1.77) 0.278 0.27 (0.02,4.15) 0.351 0.23 (0.05,0.97) 0.045* 0.01 (0,0.50) 0.020*
HCB 0.42 (0.14,1.26) 0.121 1.12 (0.17,7.40) 0.905 0.90 (0.34,2.39) 0.834 0.41 (0.08,2.00) 0.271
DDE 0.83 (0.44,1.58) 0.578 1.99 (0.52,7.59) 0.313 0.88 (0.43,1.84) 0.743 1.17 (0.35,3.97) 0.796
Exposure FL (n = 39) MM (n = 76)
OR 95% CI p-value ORb(adj) 95% CI p-value OR 95% CI p-value ORb(adj) 95% CI p-value
PCB118 0.95 (0.41,2.21) 0.904 1.04 (0.34,3.13) 0.947 1.06 (0.55,2.07) 0.856 0.62 (0.23,1.63) 0.330
PCB138 0.91 (0.31,2.67) 0.865 1.17 (0.29,4.77) 0.822 0.74 (0.32,1.70) 0.474 0.45 (0.15,1.32) 0.145
PCB153 0.94 (0.29,3.04) 0.918 1.20 (0.27,5.31) 0.814 0.73 (0.29,1.85) 0.512 0.41 (0.12,1.42) 0.159
PCB156 0.99 (0.32,3.01) 0.979 1.12 (0.24,5.36) 0.885 0.77 (0.31,1.88) 0.561 0.47 (0.14,1.62) 0.234
PCB170 1.39 (0.43,4.51) 0.580 1.65 (0.33,8.24) 0.540 0.77 (0.30,2.00) 0.588 0.42 (0.11,1.66) 0.216
PCB180 1.43 (0.44,4.63) 0.553 1.52 (0.31,7.41) 0.605 0.90 (0.35,2.31) 0.834 0.56 (0.15,2.10) 0.392
HCB 0.82 (0.36,1.86) 0.633 0.83 (0.25,2.70) 0.752 0.70 (0.30,1.61) 0.394 0.31 (0.08,1.19) 0.089
DDE 0.77 (0.41,1.48) 0.437 0.93 (0.34,2.55) 0.885 0.66 (0.37,1.15) 0.142 0.52 (0.25,1.10) 0.086
Results for the four largest subtype groups were included
OR – conditional logistic regression accounting for matching factors
OR(adj) – conditional logistic regression additionally adjusting for BMI, height, educational level, vegetables, dairy, protein, total fat, alcohol
*Significant at the 95% confidence level; Matched case-control pairs with incomplete information on potential confounders were excluded from the
adjusted analyses
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These limitations may in part explain the unexpected na-
ture of a number of the findings. However, there is some
precedent in the literature. A study in Finland has previ-
ously suggested that dioxins may act on the risk of soft-
tissue sarcoma through a J-shaped dose response curve,
and there in some support from animal models for such a
relationship [57]. The results of the ‘high exposure’ analysis
could considered to be supportive of a J-shaped curve,
however again these results were non-significant, and the
results from the quartile analysis do not support this hy-
pothesis within the confines of the exposure levels in this
study population.
Conclusion
In conclusion, we report no evidence that a higher body
burden of PCBs, DDE or HCB increased the risk of sub-
sequent NHL diagnosis. Significantly inverse associations
were noted for males with a number of the investigated
POPs. Despite extensive analyses we were unable to ex-
plain these associations. We additionally note that the
associated p-values would not be robust for multiple
testing, and that for the highest levels of exposure the
relationship was null. This study adds to the existing
body of literature and the results do not support a role
for PCBs, DDE and HCB as risk factors for NHL.
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